Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

Autor: Saad Z. Usmani, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael E. O'Dwyer, Aurore Perrot, Chris P. Venner, Katja Weisel, Joseph R. Mace, Noopur S. Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Rian Van Rampelbergh, Brenda Tromp, Maria Delioukina, Thierry Facon

Publikováno v: Usmani, S Z, Kumar, S, Plesner, T, Orlowski, R Z, Moreau, P, Bahlis, N J, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M E, Perrot, A, Venner, C P, Weisel, K, Mace, J R, Raje, N S, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Pei, H, Van Rampelbergh, R, Tromp, B, Delioukina, M & Facon, T 2021, ' Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose ', Blood, vol. 138, no. Suppl. 1, 1646 . https://doi.org/10.1182/blood-2021-146940

Introduction: The phase 3 MAIA study (NCT02252172) evaluated the addition of daratumumab (D) to lenalidomide and dexamethasone (Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM). At a median follow-up of 56.2 mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f9f03f36884b8e612f2e9301ce70667
https://portal.findresearcher.sdu.dk/da/publications/a08e2b73-7ce1-4f9b-89ae-8372d01183b1

Evidence-based guidance on venous thromboembolism in patients with solid tumours.

Autor: Shea-Budgell MA; Guideline Utilization Resource Unit, Cancer-Control Alberta, Alberta Health Services, Calgary, AB., Wu CM; Division of Hematology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB., Easaw JC; Division of Medical Oncology, Faculty of Medicine, University of Calgary Tom Baker Cancer Centre, Calgary, AB. ; Members of the Alberta Venous Thromboembolism Cancer Guideline Working Group: Jacob Easaw md p h d (chair), Peter Duggan md , Joshua Foley md , Anil Abraham Joy md , Lloyd A. Mack md ms c, Donald Morris md , Cindy Railton rn , Melissa A. Shea-Budgell ms c, Douglas Stewart md , A. Robert Turner md , Chris P. Venner md , and Janice Yurick pt .

Publikováno v: Current oncology (Toronto, Ont.) [Curr Oncol] 2014 Jun; Vol. 21 (3), pp. e504-14.